Endpoints News
Verified
Online/Digital
Endpoints News was founded in 2016 by John Carroll and Arsalan Arif to deliver the best news product in biopharma and become an essential read for industry leaders across the globe. Thanks to an ambitious team of journalists across the US, Europe and Asia and support from advertising partners, we're now read by thousands of innovative biotechs and every top 50 pharmaceutical company in the world. As a member of the Financial Times family, we're backed by the most respected global brand in business journalism and committed to providing advertisers with innovative ways to engage our growing audience of biopharma and healthcare executives across the globe. Source
Actions
Media Outlet details
| Scope | National, Trade/B2B |
|---|---|
| Language | English |
| Country | United States of America |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
Recent Articles
Search ArticlesPharma investment in UK picks up after last year’s lull, trade group says
Pharma investment in UK picks up after last year’s lull, trade group says The UK government’s move to pay more for medicines and foster a closer relationship with drugmakers appears to have led to a pickup in the … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
ARPA-H selects companies to build AI tools for heart disease
ARPA-H selects companies to build AI tools for heart disease UpDoc, Tempus AI and Atman Health will participate in a new program that aims to build FDA-authorized agentic AI tools to care for people with … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Encoded closes $275M Series F for Dravet syndrome drug
Encoded closes $275M Series F for Dravet syndrome drug Encoded Therapeutics has tacked on $275 million in new capital, closing a Series F round led by GV and an undisclosed healthcare investor. Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
FDA should follow EMA's lead on drug rejection disclosures, researchers say
September 9, 2026 12:51 PM EDT FDA should follow EMA's lead on drug rejection disclosures, researchers say The FDA’s major shift in September 2025 to begin publishing drug rejection letters is still an evolving process. But moving forward, the US agency should … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
From lab banter to a Lasker Award: The science behind narcolepsy
September 9, 2026 11:43 AM EDT From lab banter to a Lasker Award: The science behind narcolepsy The path to understanding a common sleep disorder started with lab banter and traveled through mice, dogs and more recently, the flu virus. Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Compass posts positive psilocybin data; Solstice makes $225M debut
Compass posts positive psilocybin data; Solstice makes $225M debut Plus news about Luma, Inno Medicine, Schrödinger, Assembly Biosciences, Gilead, Leyden Labs, Navion, Ridge Bio, and Opus Genetics. 📊 Compass Pathways touts one-year data … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Beeline Medicines reports promising mid-stage lupus data
September 9, 2026 07:00 AM EDT Beeline Medicines reports promising mid-stage lupus data The business of advancing shelved pharma assets continues to reap benefits, this time for Beeline Medicines and a lupus candidate provided by Bristol Myers Squibb. Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
NodThera, a decade-old NLRP3 player, plans Phase 3 and a rebrand
Geoff McDonough, Rezera CEO NodThera, a decade-old NLRP3 player, plans Phase 3 and a rebrand After tinkering with the biology of the broadly appealing anti-inflammatory NLRP3 pathway, NodThera is now plotting its pivotal trial plans for 2027. Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Exclusive: Cancer biotech TwoStep gets $62.5M to take twist on ADCs into clinic
Caitlyn Miller, TwoStep CEO Exclusive: Cancer biotech TwoStep gets $62.5M to take twist on ADCs into clinic Pfizer and Merck KGaA’s venture groups are backing a nimble cancer startup taking a different approach to the popular antibody-drug conjugate and radioligand fields. Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Tyra finds ray of sunshine in otherwise cloudy Phase 2 bladder cancer data
September 9, 2026 07:00 AM EDT Tyra finds ray of sunshine in otherwise cloudy Phase 2 bladder cancer data Tyra Biosciences wants to challenge Johnson & Johnson in a low-risk form of bladder cancer. The Phase 2 data it released Wednesday takes a step … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.